Apogee Therapeutics, Inc. priced a $350 million underwritten public offering of 5 million shares of its common stock at $70.00 per share on March 24, 2026. The offering includes an option for underwriters to purchase an additional 750,000 shares at the same price, subject to customary underwriting discounts and commissions.
The pricing was completed after the company filed a preliminary prospectus supplement with the SEC and is expected to close on March 26, 2026, pending satisfaction of customary closing conditions. The offering is part of Apogee’s ongoing strategy to maintain a strong cash position and fund its pipeline of antibody programs, including the lead candidate zumilokibart (APG777) for atopic dermatitis, asthma, and eosinophilic esophagitis.
Proceeds will be allocated to preclinical studies, clinical trials, manufacturing, and commercial readiness activities for its antibody programs, as well as general corporate purposes. The company’s recent history of capital raises—most notably a $345 million offering that closed on October 10, 2025—underscores its reliance on equity markets to support long‑term development goals.
The syndicate of underwriters includes Jefferies, TD Cowen, Stifel, and Guggenheim Securities as joint book‑running managers, with Wedbush PacGrow and BTIG serving as lead managers. Apogee filed an automatically effective shelf registration statement with the SEC on August 12, 2024, and its most recent annual report on Form 10‑K for the year ended December 31, 2025 was filed on March 2, 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.